[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553559":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":46,"collaborators":19,"id":48,"slug":19,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"TACE combined ICI","EXPERIMENTAL",[12],"Procedure: TACE with ICI",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","TACE with ICI","Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Haipeng Yu","CONTACT","022-23340123","2701","jieruke@163.com",[28],{"facility":5,"status":29,"city":30,"state":19,"zip":19,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Tianjin","China",{"type":33,"coordinates":34},"Point",[35,36],117.17667,39.14222,{"lat":36,"lon":35},[39,43],{"name":40,"role":23,"phone":41,"phoneExt":19,"email":42},"Yu Zheng","0086-22-23340123","info@tjmuch.com",{"name":44,"role":45,"phone":19,"phoneExt":19,"email":19},"Haipeng Yu, PhD","PRINCIPAL_INVESTIGATOR",{"type":45,"investigatorFullName":22,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Professor","100553559",false,"NCT06487663","TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors","Transcatheter Hepatic Artery Chemoembolization Combined With Immune Checkpoint Inhibitors for Liver Tumors","TIKET","Inclusion Criteria:\n\n* Confirmed diagnosis of HCC by histology\u002F cytology or clinical criteria\n* Sign informed consent\n* When screening for age, the age should be ≥ 18 years old\n* Eligible for TACE treatment\n* ECOG physical condition score is 0 or 1\n* No prior systemic therapy for HCC, especially immunotherapy\n* According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation\n\nExclusion Criteria:\n\n* Have any history of kidney disease or nephrotic syndrome\n* Evidence of extrahepatic spread (EHS)\n* Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control\n* Any condition representing a contraindication to TACE as determined by the investigators\n* Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding\n* Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment)\n* Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization)\n* Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.","ALL","18 Years","75 Years",{"count":59,"type":60},40,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.",[66,67,68,69],"Hepatocellular Carcinoma Non-resectable","Cholangiocarcinoma Non-resectable","Liver Metastases","Liver Malignant Tumors",[71,72,68,69],"Hepatocellular Carcinoma","Cholangiocarcinoma","2024-06-27",{"date":75,"type":76},"2024-07-05","ACTUAL",{"date":78,"type":76},"2020-10-27",{"date":80,"type":60},"2026-10-27",{"name":5,"class":6},1]